(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are IMAC Holdings, Palantir, and Kodiak Sciences.

The three biggest losers today are Akerna Corp., Guardion Health Sciences, and iHeartMedia.

Winners today

1. IMAC Holdings (IMACW) – 340%

NASDAQ ended the session with IMAC Holdings jumping 340% to $0.00 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ jumped 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Yearly Top and Bottom Value

IMAC Holdings’s stock is valued at $0.00 at 16:32 EST, below its 52-week low of $0.00.

More news about IMAC Holdings.

2. Palantir (PLTR) – 31.27%

Palantir Technologies Inc. builds and deploys software platforms for the intelligence community in the United States to assist in counterterrorism investigations and operations. The company provides Palantir Gotham, a software platform which enables users to identify patterns hidden deep within datasets, ranging from signals intelligence sources to reports from confidential informants, as well as facilitates the handoff between analysts and operational users, helping operators plan and execute real-world responses to threats that have been identified within the platform. It also offers Palantir Foundry, a platform that transforms the ways organizations operate by creating a central operating system for their data; and allows individual users to integrate and analyze the data they need in one place. In addition, it provides Palantir Apollo, a software that enables customers to deploy their own software virtually in any environment. Palantir Technologies Inc. was incorporated in 2003 and is based in Denver, Colorado.

NYSE ended the session with Palantir jumping 31.27% to $21.95 on Tuesday, after two successive sessions in a row of losses. NYSE rose 0.63% to $17,112.01, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Palantir has a trailing twelve months EPS of $0.07.

PE Ratio

Palantir has a trailing twelve months price to earnings ratio of 313.56. Meaning, the purchaser of the share is investing $313.56 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.44%.

Previous days news about Palantir

• Palantir technologies inc. (pltr) meets Q4 earnings estimates. According to Zacks on Monday, 5 February, "While Palantir Technologies Inc. Has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?", "Ahead of this earnings release, the estimate revisions trend for Palantir Technologies Inc. Mixed. "

More news about Palantir.

3. Kodiak Sciences (KOD) – 14.32%

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.

NASDAQ ended the session with Kodiak Sciences jumping 14.32% to $4.79 on Tuesday, following the last session’s upward trend. NASDAQ rose 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Kodiak Sciences has a trailing twelve months EPS of $-5.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.42%.

More news about Kodiak Sciences.

4. Histogen (HSTO) – 13.43%

Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

NASDAQ ended the session with Histogen rising 13.43% to $0.38 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Histogen has a trailing twelve months EPS of $-2.81.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -119.89%.

More news about Histogen.

5. Genprex (GNPX) – 13.37%

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

NASDAQ ended the session with Genprex jumping 13.37% to $6.70 on Tuesday while NASDAQ jumped 0.07% to $15,609.00.

Earnings Per Share

As for profitability, Genprex has a trailing twelve months EPS of $-24.4.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -158.09%.

Volume

Today’s last reported volume for Genprex is 1565690 which is 9986.27% above its average volume of 15523.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Genprex’s EBITDA is -1.74.

Moving Average

Genprex’s value is way below its 50-day moving average of $8.96 and way under its 200-day moving average of $20.21.

More news about Genprex.

6. Bilibili (BILI) – 12.87%

Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, live broadcasting, and story mode. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Bilibili rising 12.87% to $10.26 on Tuesday, following the last session’s upward trend. NASDAQ rose 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Bilibili has a trailing twelve months EPS of $-1.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.31%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Bilibili’s stock is considered to be overbought (>=80).

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 56.3% and 51.4%, respectively.

Volatility

Bilibili’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.65%, a negative 1.00%, and a positive 2.93%.

Bilibili’s highest amplitude of average volatility was 2.94% (last week), 2.83% (last month), and 2.93% (last quarter).

More news about Bilibili.

7. AMC (AMC) – 11.85%

AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. AMC Entertainment Holdings, Inc. was founded in 1920 and is headquartered in Leawood, Kansas.

NYSE ended the session with AMC jumping 11.85% to $4.11 on Tuesday while NYSE jumped 0.63% to $17,112.01.

Earnings Per Share

As for profitability, AMC has a trailing twelve months EPS of $-3.

Yearly Top and Bottom Value

AMC’s stock is valued at $4.11 at 16:32 EST, way below its 52-week high of $85.30 and above its 52-week low of $4.01.

Moving Average

AMC’s value is way under its 50-day moving average of $6.06 and way below its 200-day moving average of $26.21.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AMC’s stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

AMC’s EBITDA is 51.48.

More news about AMC.

8. Kingsoft Cloud Holdings Limited (KC) – 11.69%

Kingsoft Cloud Holdings Limited provides cloud services to businesses and organizations in China. The company offers public cloud services to customers in various verticals, including game, video, AI, e-commerce, education, and mobile internet; enterprise cloud services to customers in financial service, public service, and healthcare business, and others. It also provides IoT–smart living solutions. The company was incorporated in 2012 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Kingsoft Cloud Holdings Limited rising 11.69% to $2.77 on Tuesday, after three successive sessions in a row of losses. NASDAQ jumped 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Kingsoft Cloud Holdings Limited has a trailing twelve months EPS of $-1.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.17%.

Moving Average

Kingsoft Cloud Holdings Limited’s worth is way below its 50-day moving average of $3.46 and way under its 200-day moving average of $4.92.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Kingsoft Cloud Holdings Limited’s EBITDA is -0.99.

Revenue Growth

Year-on-year quarterly revenue growth declined by 17.5%, now sitting on 7.46B for the twelve trailing months.

More news about Kingsoft Cloud Holdings Limited.

9. Nio (NIO) – 11.34%

NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China. It offers five and six-seater electric SUVs, as well as smart electric sedans. The company also offers power solutions, including Power Home, a home charging solution; Power Swap, a battery swapping service; Power Charger and Destination Charger; Power Mobile, a mobile charging service through charging vans; Power Map, an application that provides access to a network of public chargers and their real-time information; and One Click for Power valet service. In addition, it provides repair, maintenance, and bodywork services through its NIO service centers and authorized third-party service centers; statutory and third-party liability insurance, and vehicle damage insurance through third-party insurers; repair and routine maintenance; courtesy vehicle services; roadside assistance; data packages; and auto financing and financial leasing services. Further, the company involved in the provision of energy and service packages to its users; design and technology development activities; manufacture of e-powertrains, battery packs, and components; and sales and after sales management activities. Additionally, it offers NIO Certified, a used vehicle inspection, evaluation, acquisition, and sales service. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was incorporated in 2014 and is headquartered in Shanghai, China.

NYSE ended the session with Nio jumping 11.34% to $5.99 on Tuesday, after three consecutive sessions in a row of losses. NYSE jumped 0.63% to $17,112.01, after two sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Nio has a trailing twelve months EPS of $-1.78.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.57%.

Volatility

Nio’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.50%, a negative 1.94%, and a positive 3.25%.

Nio’s highest amplitude of average volatility was 2.56% (last week), 2.86% (last month), and 3.25% (last quarter).

More news about Nio.

10. iQIYI (IQ) – 11.04%

iQIYI, Inc., together with its subsidiaries, provides online entertainment services under the iQIYI brand in the People's Republic of China. The company offers various products and services comprising internet video, online games, live broadcasting, online literature, animations, e-commerce, and social media platform. It operates a platform that provides a collection of internet video content, including professionally-produced content licensed from professional content providers and self-produced content. The company also provides membership, content distribution, and online advertising services. In addition, it operates iQIYI Mall, an e-commerce platform that focuses on entertainment-related merchandise, such as VR glasses, as well as sells electronics, apparel and accessories, and beauty and skincare products; iQIYI Show, a live broadcasting service that enables users to follow their favorite hosts, celebrities, and shows in real time through live broadcasting; and iQIYI Paopao, a social platform. Further, it is involved in the talent agency and IP licensing activities, as well as in developing Suike, a video community app. The company was formerly known as Qiyi.com, Inc. and changed its name to iQIYI, Inc. in November 2017. iQIYI, Inc. was incorporated in 2009 and is headquartered in Beijing, China. iQIYI, Inc. is a subsidiary of Baidu Holdings Limited.

NASDAQ ended the session with iQIYI jumping 11.04% to $3.52 on Tuesday, after five successive sessions in a row of losses. NASDAQ jumped 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, iQIYI has a trailing twelve months EPS of $0.13.

PE Ratio

iQIYI has a trailing twelve months price to earnings ratio of 27.08. Meaning, the purchaser of the share is investing $27.08 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.22%.

Volume

Today’s last reported volume for iQIYI is 5753580 which is 35.35% below its average volume of 8900820.

More news about iQIYI.

Losers Today

1. Akerna Corp. (KERN) – -8.94%

Akerna Corp. operates as a technology company. The company offers MJ Platform, an enterprise resource planning system to the cannabis industry; and Leaf Data Systems, a tracking system designed for government agencies. It also provides consulting services to cannabis industry; business intelligence, an infrastructure as a service tool, which delivers supply chain analytics for the cannabis, hemp, and CBD industries; and Last Call Analytics, a subscription analytics tool for alcohol brands to analyze their retail sales analytics. In addition, the company operates seed-to-sale platform that allows cultivators to track and report various stage of their cannabis growing operations, production, and sales processes. Further, it offers cannabis cultivation management and software to manage and optimize operational workflow in business analytics; and cannabis tracking technology that provides seed-to-sale-to-self data. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

NASDAQ ended the session with Akerna Corp. falling 8.94% to $0.24 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ jumped 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Akerna Corp. has a trailing twelve months EPS of $-2.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -363%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 32%, now sitting on 9.82M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Akerna Corp.’s EBITDA is -8.67.

More news about Akerna Corp..

2. Guardion Health Sciences (GHSI) – -7.6%

Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.

NASDAQ ended the session with Guardion Health Sciences dropping 7.6% to $7.90 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ rose 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Guardion Health Sciences has a trailing twelve months EPS of $-12.09.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -74.4%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is 51.3% and a drop 309.5% for the next.

More news about Guardion Health Sciences.

3. iHeartMedia (IHRT) – -7.22%

iHeartMedia, Inc. operates as a media and entertainment company worldwide. It operates through two segments, Audio, and Audio & Media Services. The Audio segment offers broadcast radio, digital, mobile, podcasts, social, program syndication, traffic, weather, news and sports data distribution, and on-demand entertainment, as well as live events, including mobile platforms and products; and operates Premiere Networks, a national radio network that produces, distributes, or represents approximately 120 syndicated radio programs and services to approximately 6,500 radio station affiliates. It also delivers real-time traffic and incident information, and weather updates, sports, and news through approximately 2,100 radio stations and 170 television affiliates, and Internet and mobile partnerships. As of December 31, 2020, this segment owned 858 radio stations, which included 244 AM and 614 FM radio stations. The Audio and Media Services segment engages in the media representation business. This segment also provides broadcast and webcast software, such as radio station automation, music scheduling, HD2 solutions, newsroom software, audio logging and archiving, single station automation, and contest tracking software; and real-time audio recognition technology to approximately 9,000 radio stations, television music channels, cable companies, satellite music networks, and Internet stations. The company was formerly known as CC Media Holdings, Inc. and changed its name to iHeartMedia, Inc. in September 2014. iHeartMedia, Inc. is headquartered in San Antonio, Texas.

NASDAQ ended the session with iHeartMedia sliding 7.22% to $2.70 on Tuesday while NASDAQ rose 0.07% to $15,609.00.

Earnings Per Share

As for profitability, iHeartMedia has a trailing twelve months EPS of $-6.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1111.52%.

Sales Growth

iHeartMedia’s sales growth is negative 7.4% for the present quarter and 6.2% for the next.

More news about iHeartMedia.

4. Innate Pharma S.A. (IPHA) – -6.69%

Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.

NASDAQ ended the session with Innate Pharma S.A. falling 6.69% to $2.51 on Tuesday while NASDAQ rose 0.07% to $15,609.00.

Earnings Per Share

As for profitability, Innate Pharma S.A. has a trailing twelve months EPS of $-0.85.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.91%.

Yearly Top and Bottom Value

Innate Pharma S.A.’s stock is valued at $2.51 at 16:32 EST, way below its 52-week high of $3.57 and way above its 52-week low of $1.81.

Moving Average

Innate Pharma S.A.’s value is below its 50-day moving average of $2.63 and way under its 200-day moving average of $2.79.

More news about Innate Pharma S.A..

5. HOOKIPA Pharma (HOOK) – -6.62%

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

NASDAQ ended the session with HOOKIPA Pharma sliding 6.62% to $0.64 on Tuesday, following the last session’s downward trend. NASDAQ rose 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, HOOKIPA Pharma has a trailing twelve months EPS of $-0.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -66.29%.

More news about HOOKIPA Pharma.

6. Huize Holding Limited (HUIZ) – -6.61%

Huize Holding Limited, together with its subsidiaries, offers insurance brokerage services in the People's Republic of China. It provides life and health insurance products, such as critical illness, illness and disease, and term life and whole life insurance products; and property and casualty insurance products, including travel, individual casualty, and corporate liability insurance products. The company offers its products through internet and mobile internet channels. It also provides technology development and Internet information consulting services; and management, marketing, investment, and financial consulting services. Huize Holding Limited was founded in 2006 and is headquartered in Shenzhen, the People's Republic of China.

NASDAQ ended the session with Huize Holding Limited dropping 6.61% to $0.60 on Tuesday while NASDAQ jumped 0.07% to $15,609.00.

Earnings Per Share

As for profitability, Huize Holding Limited has a trailing twelve months EPS of $0.17.

PE Ratio

Huize Holding Limited has a trailing twelve months price to earnings ratio of 3.51. Meaning, the purchaser of the share is investing $3.51 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.74%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 16.9%, now sitting on 1.22B for the twelve trailing months.

Sales Growth

Huize Holding Limited’s sales growth for the current quarter is negative 73%.

More news about Huize Holding Limited.

7. GreenPower Motor Company (GP) – -6.3%

GreenPower Motor Company Inc. develops, manufactures, and distributes electric vehicles for commercial markets in the United States and Canada. It offers all-electric transit, school, and charter buses. The company is based in Vancouver, Canada.

NASDAQ ended the session with GreenPower Motor Company sliding 6.3% to $2.53 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ jumped 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -55.58%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 7.1% and 56.2%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

GreenPower Motor Company’s EBITDA is -24.54.

Yearly Top and Bottom Value

GreenPower Motor Company’s stock is valued at $2.53 at 16:32 EST, way under its 52-week high of $6.05 and way higher than its 52-week low of $2.02.

More news about GreenPower Motor Company.

8. FibroGen (FGEN) – -6.17%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen falling 6.17% to $1.90 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.

More news about FibroGen.

9. UBS Group (UBS) – -5.47%

UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through four divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, and Investment Bank. The Global Wealth Management division offers investment advice and solutions, and lending solutions. This segment also provides estate and wealth planning, investing, corporate and banking, and investment management, as well as mortgage, securities-based, and structured lending solutions. The Personal & Corporate Banking division provides personal banking products and services, such as deposits, cards, and online and mobile banking, as well as lending, investments, and retirement services; and corporate and institutional solutions, including equity and debt capital markets, syndicated and structured credit, private placements, leasing, traditional financing, trade and export finance, and global custody solutions, as well as transaction banking solutions for payment and cash management. The Asset Management division offers equities, fixed income, hedge funds, real estate and private markets, indexed and alternative beta strategies, asset allocation and currency investment strategies, customized multi-asset solutions, advisory and fiduciary services, and multi-manager hedge fund solutions and advisory services. The Investment Bank division advises clients on strategic business opportunities and helps them raise capital to fund their activities; enables its clients to buy, sell, and finance securities on capital markets and to manage their risks and liquidity; distribute, trade, finance, and clear cash equities and equity-linked products; and offers clients differentiated content on major financial markets and securities. The company was formerly known as UBS AG and changed its name to UBS Group AG in December 2014. UBS Group AG was founded in 1862 and is based in Zurich, Switzerland.

NYSE ended the session with UBS Group sliding 5.47% to $28.16 on Tuesday, after two successive sessions in a row of losses. NYSE rose 0.63% to $17,112.01, after two sequential sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, UBS Group has a trailing twelve months EPS of $9.46.

PE Ratio

UBS Group has a trailing twelve months price to earnings ratio of 2.98. Meaning, the purchaser of the share is investing $2.98 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.69%.

Yearly Top and Bottom Value

UBS Group’s stock is valued at $28.16 at 16:32 EST, way under its 52-week high of $31.40 and way above its 52-week low of $17.99.

Revenue Growth

Year-on-year quarterly revenue growth grew by 39.4%, now sitting on 36.91B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, UBS Group’s stock is considered to be oversold (<=20).

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Apr 11, 2023, the estimated forward annual dividend rate is 0.55 and the estimated forward annual dividend yield is 1.9%.

More news about UBS Group.

10. KalVista Pharmaceuticals (KALV) – -5.46%

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with KalVista Pharmaceuticals dropping 5.46% to $14.98 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.07% to $15,609.00, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, KalVista Pharmaceuticals has a trailing twelve months EPS of $-3.03.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -77.89%.

Moving Average

KalVista Pharmaceuticals’s worth is way above its 50-day moving average of $11.47 and way above its 200-day moving average of $10.05.

Earnings Before Interest, Taxes, Depreciation, and Amortization

KalVista Pharmaceuticals’s EBITDA is -5.99.

Yearly Top and Bottom Value

KalVista Pharmaceuticals’s stock is valued at $14.98 at 16:32 EST, way under its 52-week high of $16.88 and way higher than its 52-week low of $6.26.

Volume

Today’s last reported volume for KalVista Pharmaceuticals is 315481 which is 20.78% below its average volume of 398254.

More news about KalVista Pharmaceuticals.

Stay up to date with our winners and losers daily report